XOMA Royalty (NASDAQ:XOMA) Announces Earnings Results, Beats Expectations By $0.16 EPS

XOMA Royalty (NASDAQ:XOMA) released its earnings results on Wednesday. The biotechnology company reported $0.12 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.16, Zacks reports. XOMA Royalty had a net margin of 45.75% and a return on equity of 10.40%. The business had revenue of $13.76 million during the quarter, compared to the consensus estimate of $11.13 million.

Here are the key takeaways from XOMA Royalty’s conference call:

• Portfolio growth — XOMA added 22 assets in 2025 (now >120 total) and has seven commercial programs, with total portfolio receipts surpassing $50M and royalty receipts of $34M (up 68% year‑over‑year).
• Strong financials and cash returns — Full‑year GAAP revenue was $52.1M (vs. $28.5M in 2024) with GAAP net income of $31.7M, positive operating cash flow, ~$83M unrestricted cash at year‑end, and $16M returned via share buybacks (≈5% of shares).
• Dealmaking and platform optionality — A December revenue‑share with Takeda reallocated mezagitamab economics into potential low‑ to mid‑single‑digit royalties plus up to $853M of milestones across nine assets, and XOMA acquired Generation Bio platforms (ctLNP and iqDNA) intended for out‑licensing to generate future royalties/milestones.
• Clinical risk realized — Two portfolio Phase III programs (Rezolute in congenital hyperinsulinism and Gossamer’s seralutinib in PAH) failed to meet primary statistical thresholds, though both sponsors plan FDA discussions to pursue potential paths forward.
• Outlook and capital structure — Management says royalties could cover operating costs by 2027 if current trends continue, the Blue Owl loan is being amortized (could be repaid by 2030), and management may pursue refinancing or preferred optimization depending on future execution.

XOMA Royalty Stock Up 5.2%

XOMA stock opened at $28.76 on Friday. The stock’s 50 day simple moving average is $26.11 and its 200 day simple moving average is $30.48. XOMA Royalty has a fifty-two week low of $18.35 and a fifty-two week high of $39.92. The company has a debt-to-equity ratio of 1.07, a quick ratio of 3.91 and a current ratio of 3.91. The company has a market cap of $356.05 million, a P/E ratio of 19.70 and a beta of 0.86.

Institutional Investors Weigh In On XOMA Royalty

Several hedge funds and other institutional investors have recently modified their holdings of the company. Woodline Partners LP raised its position in shares of XOMA Royalty by 7.9% during the first quarter. Woodline Partners LP now owns 168,550 shares of the biotechnology company’s stock worth $3,359,000 after purchasing an additional 12,284 shares during the period. Geode Capital Management LLC increased its stake in XOMA Royalty by 9.1% during the 2nd quarter. Geode Capital Management LLC now owns 203,601 shares of the biotechnology company’s stock valued at $5,132,000 after purchasing an additional 16,929 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in XOMA Royalty by 13.9% during the second quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after buying an additional 543 shares during the last quarter. Rhumbline Advisers raised its holdings in XOMA Royalty by 18.0% during the second quarter. Rhumbline Advisers now owns 13,249 shares of the biotechnology company’s stock worth $334,000 after buying an additional 2,019 shares during the last quarter. Finally, Marshall Wace LLP lifted its stake in shares of XOMA Royalty by 12.2% in the second quarter. Marshall Wace LLP now owns 16,308 shares of the biotechnology company’s stock valued at $411,000 after buying an additional 1,775 shares in the last quarter. Institutional investors own 95.92% of the company’s stock.

XOMA Royalty News Summary

Here are the key news stories impacting XOMA Royalty this week:

• Positive Sentiment: Q4 results beat expectations — XOMA reported $0.12 EPS and $13.76M revenue for Q4 (both above consensus), which the market interpreted as a “double beat” and cited management signaling pipeline catalysts ahead. XOMA Royalty Jumps After Q4 Double Beat, Signals Pipeline Catalysts Ahead
• Positive Sentiment: Strong 2025 cash receipts and royalty growth — XOMA reported over $50M of cash receipts in 2025 (including $33.6M royalties and $16.9M milestones) and royalties up ~68% vs. 2024, supporting recurring revenue visibility. XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements
• Positive Sentiment: Analyst/institutional support — recent buy/outperform notes and above‑average price targets (median targets well above the current price) plus institutional additions were highlighted in coverage, which can lift sentiment and liquidity. XOMA ($XOMA) Releases Q4 2025 Earnings
• Positive Sentiment: Insider buying / hedge fund activity — the CEO made a sizeable open‑market purchase recently and several institutional investors increased positions, a constructive sign for investor confidence. XOMA ($XOMA) Releases Q4 2025 Earnings
• Positive Sentiment: Improved technical/momentum signals — coverage highlighted improved relative strength and momentum, which can attract short‑term momentum traders. Stocks showing improved relative strength: XOMA royalty
• Neutral Sentiment: Declared quarterly preferred dividends — the board authorized cash dividends on Series A/B preferred shares (routine for preferred holders; modest cash outflow). XOMA Royalty Declares Quarterly Preferred Stock Dividends
• Neutral Sentiment: Earnings call transcript posted — management commentary is available for detail (useful for confirming timing of catalysts, but market reaction depends on concrete pipeline milestones). XOMA Royalty Corporation (XOMA) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Ongoing risks: sell‑side models still forecast a FY loss and there were some insider sales (CFO), which can temper optimism and act as a headwind if future royalty receipts or pipeline milestones disappoint. XOMA ($XOMA) Releases Q4 2025 Earnings XOMA Royalty Price Performance

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Leerink Partners reiterated an “outperform” rating on shares of XOMA Royalty in a report on Tuesday, February 24th. Weiss Ratings reiterated a “hold (c-)” rating on shares of XOMA Royalty in a report on Monday, December 29th. Zacks Research lowered XOMA Royalty from a “hold” rating to a “strong sell” rating in a research note on Tuesday, March 10th. UBS Group set a $76.00 price target on XOMA Royalty in a report on Tuesday, December 9th. Finally, TD Cowen raised shares of XOMA Royalty to a “hold” rating in a research report on Friday, February 13th. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $61.60.

XOMA Royalty Company Profile

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.